Diovan Articles
Zeneca Sees Strong Growth Against The Odds
8 August 1997
2005 US CHF Market: 27% Angiotensin II Antagonists
6 August 1997
Antihypertensive Sales "Set To Decline"
1 August 1997
SB's Eprosartan Debuts In Germany
31 July 1997
Diovan Reduces LVH
16 July 1997
Novartis Unveils Strong Product Pipeline
1 July 1997
Diovan "More Efficacious" Than Cozaar, New Data
9 June 1997
Health Care Fuels Strong 1997 Start For Novartis
21 April 1997
US Launch For Novartis' Valsartan
10 March 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
No Hidden Surprises From US FTC For Birth Of Novartis
6 January 1997
Ciba Launches Femara And Diovan In The UK
2 December 1996
Germany Sees First Launch For Ciba's Diovan
15 July 1996
Eruope Stock Comment
3 June 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Ciba Health Care Sales Rise 8%
29 January 1996
Angiotensin II Antagonists In Europe: What Future?
6 November 1995
Sanofi's Mid-term Pipeline "One Of The Most Promising
23 October 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
